Author(s): Hanna I. Severina, Svitlana M. Gubar, Ivan V. Bezruk, Anna S. Materiienko, Liudas Ivanauskas, Vera A. Bunyatyan, Sergiy M. Kovalenko, Olha O. Scupa, Victoriya A. Georgiyants

Email(s): severina.ai@ukr.net

DOI: 10.52711/0974-360X.2021.00561   

Address: Hanna I. Severina1*, Svitlana M. Gubar1, Ivan V. Bezruk1, Anna S. Materiienko1, Liudas Ivanauskas2, Vera A. Bunyatyan3, Sergiy M. Kovalenko4, Olha O. Scupa5, Victoriya A. Georgiyants1
1National University of Pharmacy, 53 Pushkinska Str., 61002, Kharkiv, Ukraine.
2Lithuanian University of Health Sciences, Sukileliu Av. 13, Kaunas, LT-50162, Lithuania.
3 Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University). 8 Trubeckaya St., Moscow 119991, Russia.
4V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv, 61077, Ukraine.
5National Pirogov Memorial Medical University, 56 Pirogova St., Vinnytsya 21018, Ukraine.
*Corresponding Author

Published In:   Volume - 14,      Issue - 6,     Year - 2021


ABSTRACT:
1-(4-methoxyphenyl)-5-[2-[4-(4-methoxyphenyl)piperazin-1-yl]-2-oxo-ethyl]pyrazolo[3,4-d]pyrimidin-4-one has been reported as a promising new anticonvulsant drug candidate with a code name “Epimidin”. A new HPLC method for the related substances determination of potential active pharmaceutical ingredient has been developed and validated. The method uses ACE C18 column (250x4.6mm, 5µm) and gradient elution. Mobile phase consisted of a mixture of methanol R (mobile phase A) and phosphate buffer solution with triethanolamine, adjusted to pH 7.0 (mobile phase B). During the analysis, the ratio of mobile phases was changing according to a gradient mode at a flow rate of 1ml/min. The DAD detection was set at 240nm. The method was validated according to the ICH guidelines and requirements of State Pharmacopoeia of Ukraine. Drug substance was thoroughly explored for stability assessments under various stress conditions such as high temperature, as well as the influence of strong acid and base and oxidizing agents. The obtained solutions were analyzed by HPLC and LC/MS. It has been shown that the substance Epimidin was not resistant to the action of peroxide, alkali and acid decomposition – the mentioned stress conditions lead to the formation of unidentified impurities.


Cite this article:
Hanna I. Severina, Svitlana M. Gubar, Ivan V. Bezruk, Anna S. Materiienko, Liudas Ivanauskas, Vera A. Bunyatyan, Sergiy M. Kovalenko, Olha O. Scupa, Victoriya A. Georgiyants. Development and Validation of HPLC Determination of related Substances in A Novel Anticonvulsant agent Epimidin. Research Journal of Pharmacy and Technology. 2021; 14(6):3223-1. doi: 10.52711/0974-360X.2021.00561

Cite(Electronic):
Hanna I. Severina, Svitlana M. Gubar, Ivan V. Bezruk, Anna S. Materiienko, Liudas Ivanauskas, Vera A. Bunyatyan, Sergiy M. Kovalenko, Olha O. Scupa, Victoriya A. Georgiyants. Development and Validation of HPLC Determination of related Substances in A Novel Anticonvulsant agent Epimidin. Research Journal of Pharmacy and Technology. 2021; 14(6):3223-1. doi: 10.52711/0974-360X.2021.00561   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-6-51


REFERENCES:
1.    Vossler, D. G., Weingarten, M., Gidal, B. E. American epilepsy society treatments committee. Summary of antiepileptic drugs available in the United States of America: working toward a world without epilepsy. Epilepsy Currents. 2018; 18.4_suppl: 1-26.
2.    Vogt, V.L., Äikiä, M., Del Barrio, A., Boon, P., Borbély, C., Bran, E., Braun, K., Carette, E., Clark, M., Cross, J.H., Dimova, P., Fabo, D., Foroglou, N., Francione, S., Gersamia, A., Gil-Nagel, A., Guekht, A. Current standards of neuropsychological assessment in epilepsy surgery centers across Europe. Epilepsia. 2017; 58(3): 343-355.
3.    Janmohamed, M., Brodie, M.J., Kwan, P. Pharmacoresistance - Epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 2020; 168: 107790
4.    Severina, A. I., Georgiyants, V. А., Shtrygol, S. Yu., Kavraiskyi, D. P. Synthesis of N-substituted derivatives of 1-(4-methoxyphenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one as potential anticonvulsants. Scripta scientifica pharmaceutica. 2016; 3(2): 36-40.
5.    The invention patent №116226 A61K 31/505 (2006.01), A61P 21/00, C07D 231/54 (2006.01) C07D 471/04 (2006.01). 5-R-1-Aryl-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-ones, having anticonvulsant activity. Severina H. I., Kavraiskyi D. P., Shtrygol S. Yu., Georgiyants V. А. National University of Pharmacy. Declared 06.07.2015 № a 2015 06662. Published 26.02.2018. Bulletin 4.
6.    Hodge, H. C., Sterner, J. H. Tabulation of toxicity classes. American Industrial Hygiene Association Quarterly. 1949; 10(4): 93-96.
7.    Jain, D., Basniwal, P. K. Forced degradation and impurity profiling: recent trends in analytical perspectives. Journal of Pharmaceutical and Biomedical Analysis. 2013; 86: 11-35.
8.    ICH Harmonised Tripartite Guideline. Impurities in new drug substances Q3A (R2). In: Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. 2006.
9.    Roy, J. Pharmaceutical impurities—a mini-review. AAPs PharmSciTech, 2002; 3.2: 1-8. (https ://doi.org/10.1208/pt030 206—99943)
10.    Venkannaa, G., Madhusudhan, G., Mukkanti, K., Sampath Kumar, Y. Identification synthesis of process-related impurities (substances) ethyl-4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate [key intermediate of Olmesartan medoxomil (Antihypertensive drug)]. Asian Journal of Research in Chemistry. 2015; 8(5): 307-317.
11.    Yamgar, R., Sawant, S. Synthesis and characterization of novel impurities in Paroxetine Hydrochloride hemihydrate and adopting QbD principles to built in quality in process of final drug substance. Asian Journal of Research in Chemistry. 2012; 5(3): 329-335.
12.    Li, Y., Liu, D. Q., Yang, S., Sudini, R., McGuire, M. A., Bhanushali, D. S., Kord, A. S. Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping. Journal of Pharmaceutical and Biomedical Analysis. 2010; 52(4): 493-507.
13.    Pirrone, G. F., Mathew, R. M., Makarov, A. A., Bernardoni, F., Klapars, A., Hartman, R., Limanto J., Regalado, E. L. Supercritical fluid chromatography-photodiode array detection-electrospray ionization mass spectrometry as a framework for impurity fate mapping in the development and manufacture of drug substances. Journal of Chromatography B. 2018; 1080: 42-49.
14.     Kjell, D. P., Hallberg, D. W., Kalbfleisch, J. M., McCurry, C. K., Semo, M. J., Sheldon, E. M., Spitler T. J., Wang, M. Determination of the source of the N-methyl impurity in the synthesis of pemetrexed disodium heptahydrate. Organic Process Research & Development. 2005; 9(6): 738-742.
15.    Hongliu Wu. Pemetrexed intermediate and preparation method thereof. China Unexamined APPLIC, open to Public inspection CN20071024889. 06 Jul 2007.
16.    Liu, D. Q., Chen, T. K., McGuire, M. A., Kord, A. S. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process. Journal of Pharmaceutical and Biomedical Analysis. 2009; 50(2): 144-150.
17.    Vadgaonkar, A. R., Kasture, V. S., Gosavi, S. A., Pawar, S. S., Jadhav, G. P. (2014). Synthesis, isolation, characterisation and quantification of process related impurity of zidovudine. Rasayan Journal Chemistry. 2014; 7(2): 181-189.
18.     Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products, United States Department of Health and Human Services, Food and Drug Administration, November 2003.
19.    Gupta, A., Rawat, S., Gandhi, M., Yadav, J.S. Method development and acid degradation study of doxofylline by RP-HPLC and LC-MS/MS. Asian Journal of Pharmaceutical Analysis. 2011; 1(1): 10-13.
20.    Holm, R., Elder, D. P. Analytical advances in pharmaceutical impurity profiling. European Journal of Pharmaceutical Sciences, 2016; 87: 118-135.
21.    Liu, M., Wang, J., Liu, P. HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276). Journal of Pharmaceutical and Biomedical Analysis, 2016; 131: 429-435.
22.    Swathi, P., Rajeswar Dutt, K., V Rao, K. N., Alagar Raja, M. RP-HPLC Method development and validation for estimation of Sofosbuvir in pure and tablet dosage form. Asian Journal of Pharmacy and Technology. 2017; 7 (3): 153-156.
23.    Prakash, S. S., Kalyan, K., Raju, S.A., Danki, L.S.. Development and validation of spectrophotometric methods for the estimation of Gemcitabine in bulk drug and its pharmaceutical formulations. Research Journal of Pharmacy and Technology. 2011; 4(6): 951-954.
24.    Annapurna, M. M., Baswani R., Pradhan D.P. New Stability Indicating RP-UFLC Method for the Determination of Flucytosine – An Anti Fungal Agent. Acta Scientific Pharmaceutical Sciences, 2019; 3(5): 84-90.
25.    Satyanarayana, L., Naidu, S.V., Narasimha Rao, M., Reddy Suma Latha. The estimation of Nilotinib in capsule dosage form by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2011;  1(4): 100-102.
26.    Markelj, J., Zupančič, T., Pihlar, B. Optimization of high performance liquid chromatography method for simultaneous determination of some purine and pyrimidine bases. Acta Chimica Slovenica. 2015; 63(1): 8-17.
27.    Narayana, M. B. V., Chandrasekhar, K. B., Rao, B. M. (2014). A validated specific stability-indicating RP-HPLC assay method for ambrisentan and its related substances. Journal of Chromatographic science, 2014; 52(8): 818-825.
28.    Pasha, S. I., Ibrahim, M., Balram, V. M. Stability Indicating Analytical Method Development, Validation, Method Transfer And Impurity Profile (Related Substances) of 2,4-Dihydroxy-5-Fluoropyrimidine by Liquid Chromatography. International Journal of Pharmaceutical Research and Applications, 2016; 1(1): 53-59
29.    Sharma, M., Upadhyay, N. K., Mahindroo, N. Stability-indicating HPLC Method for Determination of 7, 8, 9, 10-tetrahydroazepino [2, 1b] quinazolin-12 (6H)-one, a Potential Anticancer Agent. Indian Journal of Pharmaceutical Sciences, 2017; 78(6): 769-774.
30.    Kumar, P., Dhande, P., Mazlee, M., Yaman, S. M., Chandran, N., Makhtar, M., Shekhawat, D., Lanke, S., Kumar, R., Mhetre, S. A controlled, efficient and robust process for the synthesis of an epidermal growth factor receptor inhibitor: Afatinib Dimaleate. Chemical Reports, 2019; 1(1): 3-12.
31.    Metwally, F. H., Abdelkawy, M., Abdelwahab, N. S. Application of spectrophotometric, densitometric, and HPLC techniques as stability indicating methods for determination of Zaleplon in pharmaceutical preparations. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2007; 68(5): 1220-1230.
32.    Suganthi, A., Ravi, T.K. Stability indicating RP-HPLC method for the determination of fenoverine in bulk and formulation. Research Journal of Pharmacy and Technology, 2011; 4(2): 237-241.
33.    Raveendra Babu, G., Srinivasa Rao, J., Suresh Kumar, K., Jayachandra Reddy, P. Stability indicating Liquid Chromatographic Method for Aripiprazole. Asian Journal of Pharmaceutical Analysis. 2011; 1(1): 03-07.
34.    Kiran Kumar, V., Appala Raju, N., Namratha Rani, Seshagiri Rao, J.V.L.N., Satyanarayana, T. The estimation of Irinotecan HCl in parenterals by RP-HPLC. Asian Journal of Research in Chemistry. 2009; 2(1): 54-56.
35.    State Pharmacopoeia of Ukraine: in 3 volumes. Kharkiv: State enterprise “Ukrainian scientific pharmacopoeial center of medicines quality”, 2-nd ed., Vol. 1., 2014
36.    PubChem Identifier: CID 2497546. URL: https://pubchem.ncbi.nlm.nih.gov/compound/ 2497546.
37.    ICH harmonized tripartite guideline Q2 (R1). Validation of Analytical Procedures: Text and Methodology Q2 (R1). In: Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 2005.
38.    ICH Harmonised Tripartite Guideline. Impurities in new drug products Q3B (R2). In: International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use, Geneva, Switzerland. 2006.

Recomonded Articles:

Author(s): Ravindranath S. Misal, Vishawas R. Potphode, Vijay R. Mahajan

DOI: 10.5958/0974-360X.2017.00218.9         Access: Open Access Read More

Author(s): Niharika, Navneet Verma

DOI: 10.5958/0974-360X.2016.00182.7         Access: Open Access Read More

Author(s): A. S. K. Sankar, B. Datchayani, N. Balakumaran, Mohammed Rilwan, R. Subaranjani

DOI: 10.5958/0974-360X.2017.00047.6         Access: Open Access Read More

Author(s): Peethala Prathyusha, Raja Sundararajan, Palyam Bhanu, Mathrusri Annapurna Mukthinuthalapati

DOI: 10.5958/0974-360X.2020.00507.7         Access: Open Access Read More

Author(s): V. Shirisha, Somsubhra Ghosh, B. Rajni, David Banji

DOI: Not Available         Access: Open Access Read More

Author(s): Vijayalakshmi. S , Disalva. X, Chittaranjan Srivastava, Arun A

DOI: 10.5958/0974-360X.2019.00520.1         Access: Open Access Read More

Author(s): Yarnykh T. G., Kotvitska A. A., Tykhonov A. I., Rukhmakova O. A.

DOI: 10.5958/0974-360X.2020.00614.9         Access: Open Access Read More

Author(s): R. P. Bhole, S. R. Jagtap, K. B. Chadar, Y. B. Zambare

DOI: 10.5958/0974-360X.2020.00189.4         Access: Open Access Read More

Author(s): Suha Alnaeb, Youssef Alahmad, Saleh Trefi

DOI: 10.5958/0974-360X.2019.01035.7         Access: Open Access Read More

Author(s): Dhara Parekh, Pankaj Kapupara, Ketan Shah

DOI: dharaparekh92@gmail.com         Access: Open Access Read More

Author(s): Katare Varsha B., Bhutkar M. A., Kumbhar A. P., Pol S. K., Katare P. B.

DOI: Not Available         Access: Open Access Read More

Author(s): R Deveswaran, S Bharath, BV Basavaraj, Sindhu Abraham, Sharon Furtado, V Madhavan

DOI:         Access: Open Access Read More

Author(s): Bahubali N. Patil, Vamshi Krishna Tippavajhala, Girish Pai K

DOI: 10.5958/0974-360X.2019.00140.9         Access: Open Access Read More

Author(s): Shrivastava Alankar, Jain R., Agrawal R.K., Ahirwar D.

DOI:         Access: Open Access Read More

Author(s): Mythili. L, GNK. Ganesh, C. Monisha, Kayalvizhi. R

DOI: 10.5958/0974-360X.2019.00426.8         Access: Open Access Read More

Author(s): U.S Mahadeva Rao, Khamsah Suryati Mohd, Abdurrazaq Muhammad, Bashir Ado Ahmad, Mohaslinda Mohamad, Rosmawati Mat Ali

DOI: Not Available         Access: Open Access Read More

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags